Akums Drugs & Pharmaceuticals (AKUMS) Fundamentals 2026 — P/E 41.8x, Revenue Analysis | SniperIQ
Akums Drugs & Pharmaceuticals (AKUMS) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹10,656 Crore, trading at ₹696.00 on the NSE. This SniperIQ fundamentals page covers Akums Drugs & Pharmaceuticals's valuation (P/E 41.8x, P/B 3.2x), profitability (net margin 5.9%), revenue (₹4,359 Crore in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Akums Drugs & Pharmaceuticals's market cap?
Akums Drugs & Pharmaceuticals (AKUMS) has a market capitalization of approximately ₹10,656 Crore, trading at ₹696.00 on the NSE. Market cap moves with the live share price.
What is Akums Drugs & Pharmaceuticals's P/E ratio?
Akums Drugs & Pharmaceuticals's trailing twelve-month P/E ratio is 41.8x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Akums Drugs & Pharmaceuticals?
Akums Drugs & Pharmaceuticals runs a net profit margin of 5.9%, a gross margin of 31.6%, and an operating margin of 8.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Akums Drugs & Pharmaceuticals generate?
Akums Drugs & Pharmaceuticals reported revenue of ₹4,359 Crore for fiscal year 2025, with net income of ₹255 Crore and earnings per share (EPS) of 16.67. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Akums Drugs & Pharmaceuticals pay a dividend?
Akums Drugs & Pharmaceuticals offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Akums Drugs & Pharmaceuticals financially healthy?
Akums Drugs & Pharmaceuticals carries a debt-to-equity ratio of 0.05x and a current ratio of 3.25x, with a market beta of 0.76. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Akums Drugs & Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Akums Drugs & Pharmaceuticals (AKUMS) the key facts are: market cap ₹10,656 Crore, P/E 41.8x, revenue ₹4,359 Crore, 52-week range 409.3-714.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Akums Drugs & Pharmaceuticals's full fundamentals live
Get Akums Drugs & Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.